PDCD1 and breast carcinoma: In a preclinical model of BRCA1-mutated breast cancer, the combination of a DNA-damaging agent, such as cisplatin, and immune checkpoint inhibitors (anti-CTLA4 and/or anti-PD-1) was found to be synergistic.